HER2 Monoclonal Antibody Camptothecin Derivative Conjugate

Mechanism

Related News

Three Cancer Drug Trials Advance: AIM Plans Phase 3, Innovent Doses First Patient

Mar 02, 2026

AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.

Innovent Doses First Patient in Phase 3 Trial of IBI354 for HER2-Positive Breast Cancer

Feb 13, 2026

Innovent Biologics has dosed the first participant in its pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, a HER2-targeted antibody-drug conjugate, as first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer.